Account
Insider Insights
30.01.2024
Financing of new orphan drugs in Spain increases i...

Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and ...

Read more
Insider Insights
30.01.2024
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more
Webinar
06.10.2023
Orphan Medicine Market Access in Europe

Webinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...

Read more
Articles
07.09.2023
HUMN legislation – enabler or barrier for advanc...

This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...

Read more
Articles
07.09.2023
Prescription Price Puzzles: The Sky-High Cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
Case Studies
26.04.2023
Gaining payer insights

Our client required focused payer value messages for their PUMA product as payers were not recognizi...

Read more
Case Studies
26.04.2023
Development of an EU P&R strategy

Our client needed to understand the clinical and economic evidence requirements that drive payer dec...

Read more
Case Studies
26.04.2023
Gaining payer insights

Our client required focused payer value messages for their orphan drug as payers were not recognizin...

Read more
News
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
News
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.